Search results for: Multi-Indication Medicines
Filter search results
Exploring the Link Between Health and Wealth in Government Decision Making
16 May 2013
…does decision making take into account that the investment in health care, including medicines interventions, can improve economic output. Barriers to a broader perspective included system fragmentation that precludes taking…
What Is the Role of Cost-Effectiveness Evidence in US Health Care?
31 July 2013
…Chambers discussed to what extent coverage decisions for medicines are consistent with cost-effectiveness evidence and what might be gained by explicitly including economic evidence in Medicare coverage policy — in…
ISPOR Task Force Report on Performance-Based Risk-Sharing Arrangements
28 August 2013
…Severens, Erasmus University Rotterdam; Paolo Siviero, AIFA (Italian Medicines Agency); and Miguel Sleeper, GlaxoSmithKline. For a recent slide presentation by Prof Towse that discusses PBSRAs, please click here. …
Seminar Updates Project on Time Lags in Medical Research
8 October 2013
…at medicines (amlodipine and olanzapine), screening (for abdominal aortic aneurysms), public health (smoking reduction), psychosocial interventions (cognitive behavioural therapy for depression and for schizophrenia), and service reorganisations (early intervention to…
Critique of Research Proposing to Lower NICE’s Cost-per-QALY Threshold to £12,936
2 December 2013
…quality-adjusted life-year (QALY). Therefore, they conclude, NICE should not approve medicines with a cost-per-QALY greater than this threshold. The critique by OHE’s Barnsley et al accepts the premise that NICE’s…
Spotlight on OHE: Opportunity Costs of NICE Decisions in Wales and HESG 2015
20 January 2015
…in the OHE research paper with the same title [OHE Research paper 14/02]. This presentation was part of the “Medicines Knowledge Base” series of lunchtime briefing seminars organised by…
Benefiting Sooner from Medical Research
3 February 2015
…sources. The technologies in the seven case studies range from medicines to public health measures to behavioural therapy to a service reorganisation aimed at early intervention. Overall we found…
OHE Occasional Paper Critiques the Claxton et al. £13,000 per QALY Estimate
24 February 2015
…life year (QALY) in the English NHS in 2008/09. NICE currently uses a cost per QALY threshold of £20,000 to £30,000 – and so recommends many medicines and other…
OHE Briefing on Incentives to Follow Best Practice in Health Care
27 February 2015
…medicines or other health technologies. These incentives include monetary and non-monetary rewards. In the first section of the Briefing, the authors report the results of a review of empirical…